Jason Hoitt's most recent trade in Stoke Therapeutics Inc was a trade of 1,762 Common Stock done at an average price of $31.3 . Disclosure was reported to the exchange on March 17, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Stoke Therapeutics Inc | Jason Hoitt | Chief Patient Officer | Sale of securities on an exchange or to another person at price $ 31.28 per share. | 17 Mar 2026 | 1,762 | 10,445 (0%) | 0% | 31.3 | 55,122 | Common Stock |
| Stoke Therapeutics Inc | Jason Hoitt | Chief Patient Officer | Sale of securities on an exchange or to another person at price $ 32.74 per share. | 17 Mar 2026 | 1,033 | 12,955 (0%) | 0% | 32.7 | 33,820 | Common Stock |
| Stoke Therapeutics Inc | Jason Hoitt | Chief Patient Officer | Sale of securities on an exchange or to another person at price $ 33.38 per share. | 17 Mar 2026 | 748 | 12,207 (0%) | 0% | 33.4 | 24,965 | Common Stock |
| Stoke Therapeutics Inc | Jason Hoitt | Chief Patient Officer | Sale of securities on an exchange or to another person at price $ 31.79 per share. | 17 Mar 2026 | 139 | 10,306 (0%) | 0% | 31.8 | 4,419 | Common Stock |
| Stoke Therapeutics Inc | Jason Hoitt | Chief Patient Officer | Sale of securities on an exchange or to another person at price $ 32.87 per share. | 17 Mar 2026 | 30 | 10,276 (0%) | 0% | 32.9 | 986 | Common Stock |
| Stoke Therapeutics Inc | Jason Hoitt | Chief Patient Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2026 | 10,000 | 30,000 | - | - | Restricted Stock Units | |
| Stoke Therapeutics Inc | Jason Hoitt | Chief Patient Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2026 | 10,000 | 13,988 (0%) | 0% | 0 | Common Stock | |
| Stoke Therapeutics Inc | Jason Hoitt | Chief Patient Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2026 | 72,000 | 72,000 | - | - | Employee Stock Option (Right to Buy) | |
| Stoke Therapeutics Inc | Jason Hoitt | Chief Patient Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2026 | 48,000 | 48,000 | - | - | Restricted Stock Units |